08 Sep, 2011 ALN-APC for Hemophilia
We have launched our fourth program as part of our Alnylam 5×15 product development strategy. ALN-APC is an RNAi therapeutic for the treatment of hemophilia, and as with our other Alnylam 5×15 programs, targets protein C, a genetically defined target, and will utilize Alnylam’s existing delivery platform.
With the opportunity to measure clinically meaningful biomarkers in a Phase I trial, we expect to achieve early human data followed by execution on what we believe are clear and rapid development and commercialization paths. ALN-APC is expected to advance into clinical development in 2013. We are very encouraged by the pre-clinical data we have seen to date which includes robust and durable silencing of protein C, a key regulator of blood coagulation.